| Literature DB >> 26844676 |
Xiao-Tong Wang1,2, Qiu-Yuan Xia1, Hao Ni1,2, Zi-Yu Wang3, Sheng-Bing Ye1, Rui Li1, Xuan Wang1, Jing-Huan Lv1, Shan-Shan Shi1, Heng-Hui Ma1, Zhen-Feng Lu1, Qin Shen1, Xiao-Jun Zhou1, Qiu Rao1,2.
Abstract
Recently, an increasing number of TFE3 rearrangement-associated tumours have been reported, such as TFE3 rearrangement-associated perivascular epithelioid cell tumours (PEComas), melanotic Xp11 translocation renal cancers and melanotic Xp11 neoplasms. We have suggested that these tumours belong to a single clinicopathological spectrum. 'Xp11 neoplasm with melanocytic differentiation' or 'melanotic Xp11 neoplasm' have been proposed to designate this unique neoplasm. Herein, we describe the first case of an Xp11 neoplasm with melanocytic differentiation to be described in the prostate, bearing the novel NONO-TFE3 gene fusion. This study both adds to the spectrum regarding melanotic Xp11 neoplasms and expands its gene fusion spectrum. Moreover, we discuss the relationship of these rare tumours to neoplasms such as conventional PEComas, alveolar soft part sarcomas, malignant melanomas, clear cell sarcomas and Xp11 translocation renal cancers.Entities:
Keywords: NONO; PSF/SFPQ; TFE3; Xp11 translocation; fluorescence in-situ hybridization; gene fusion; melanocytic differentiation; perivascular epithelioid cell tumour; prostate
Mesh:
Substances:
Year: 2016 PMID: 26844676 DOI: 10.1111/his.12949
Source DB: PubMed Journal: Histopathology ISSN: 0309-0167 Impact factor: 5.087